Cervomed Inc CRVO

$1.67 -0.02 (-1.18%)

Valuation

Market cap
25,568,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
543,700
Avg volume
551,084
Day's range
$1.65 – $1.90
Shares out
15,129,000
Stochastic %K
43%
Beta
-0.62
Analysts
Strong Buy
Price target
$17.83

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

Adorno99 Nov 17, 10:43 AM
$CRVO just be patient. This drug is a winner and eventually shorts will have to cover. Partnership in the works or Booger will put up his own cash. Scabby can go to hell.
0 replies
focafoca99 Nov 17, 5:39 AM
$CRVO announces 24-week biomarker data showing neflamapimod cut neurofilament light chain in nfvPPA patients. https://www.rapidticker.com/news/crvo-cervomed-presents-interim-data-at-c25b81
0 replies
BPler Nov 17, 5:07 AM
$CRVO Every "side quest" with no negatives or side effects is always a small win for P3 DLB as well, as current offlabel treatment methods comes with severe risks
0 replies
BPler Nov 17, 5:02 AM
$CRVO https://ir.cervomed.com/news-releases/news-release-details/cervomed-presents-interim-data-ctad-2026-showing-neflamapimod
0 replies
StellaLunaSun Nov 16, 10:35 PM
$CRVO Selling off the shares now makes absolutely no sense. Before the October data were released, we had been stable at $2.50 for a long time; then, in the run-up to the data, we rose to almost $4; after the data were released, we fell back to $2.70 – so the ‘sell-off’ was simply the ‘pump’ ahead of the date. The reason we subsequently ended up at $1.39 was not due to the data itself, but because, AFTERWARDS, very old news items were deliberately published with a current date, suggesting that Cervomed had failed; it was, in fact, market manipulation. This means that even before the October data, the stable price was $2.50. There was no rally back to that $2.50 now. So it makes absolutely no sense to sell off a rally that didn’t actually happen, and the data are very good and promising. Anyone selling now is just being really stupid.
1 replies
Houseofsweeps Nov 16, 9:17 PM
$CRVO more exposure to the drug the better these patients got the less exposure the worse they got Same as before and is why they are going to 100 BID
2 replies
TricksterT Nov 16, 9:12 PM
$CRVO https://www.stocktitan.net/news/CRVO/cervo-med-presents-interim-data-at-ctad-2026-showing-neflamapimod-upptar88foab.html
0 replies
TricksterT Nov 16, 9:05 PM
$CRVO https://www.streetinsider.com/dr/news.php?id=27354171&gfv=1
0 replies